You are here: Home > Projects and Research lines > A randomized, double-blind, multi-center phase III study of brivanib plus best supportive care versus placebo versus best supportive care in subjects with advanced HCC who failed sorafenib treatment. (BRISK)
Projects and Research lines
A randomized, double-blind, multi-center phase III study of brivanib plus best supportive care versus placebo versus best supportive care in subjects with advanced HCC who failed sorafenib treatment. (BRISK)

Bristol-Myers Squibb

Clinical research: Clinical trials in liver cancer

Liver Cancer Translational Research Laboratory

BCLC-IDIBAPS, Liver Unit, Hospital Clínic · Esther Koplowitz Center, 3rd Floor
Rosselló 153 · 08036 Barcelona · Tel: +34 93 227 9155

© Liver Cancer Translational Research Laboratory - IDIBAPS 2011 - 2017